Abstract
Cytochrome P450 isozymes (CYPs) from the CYP1 and CYP2 families located primarily in extra-hepatic tissues represent ideal candidates for chemotherapeutic drug development because: 1.) They are usually involved in the metabolism of endogenous substrates that are important for cell homeostasis and growth 2.) The over-expression of certain CYPs has been reported in various malignancies 3.) There has been much clinical success with inhibitors of CYPs involved in hormone synthesis. The most ideal candidates for chemotherapeutic drug development will be discussed in terms of their biological importance and relevant substrates. This review will focus on: 1.) CYP1A1 and CYP1B1 from the CYP1 family because of the dual role these enzymes play in the bioactivation of known carcinogens and endogenous compounds. 2.) The targeting of CYPs in hypoxic environments as a therapeutic strategy. 3.) CYP2J2 and its role in the metabolism of arachidonic acid to epoxyeicosatrienoic acids and angiogenesis will also be examined. While much progress has been made towards understanding the role of CYPs in extrahepatic tissue, future studies focused on the development of selective inhibitors coupled with appropriate delivery systems that would target the tumor micro-environments could lead to significant advancement in chemotherapeutic strategies.
Keywords: Angiogenesis, carcinogenesis, chemotherapeutic, cytochrome P450, hypoxia, pharmacogenetics.
Current Topics in Medicinal Chemistry
Title:Extra-Hepatic Isozymes from the CYP1 and CYP2 Families as Potential Chemotherapeutic Targets
Volume: 13 Issue: 12
Author(s): Brianne S. Raccor and Rudiger Kaspera
Affiliation:
Keywords: Angiogenesis, carcinogenesis, chemotherapeutic, cytochrome P450, hypoxia, pharmacogenetics.
Abstract: Cytochrome P450 isozymes (CYPs) from the CYP1 and CYP2 families located primarily in extra-hepatic tissues represent ideal candidates for chemotherapeutic drug development because: 1.) They are usually involved in the metabolism of endogenous substrates that are important for cell homeostasis and growth 2.) The over-expression of certain CYPs has been reported in various malignancies 3.) There has been much clinical success with inhibitors of CYPs involved in hormone synthesis. The most ideal candidates for chemotherapeutic drug development will be discussed in terms of their biological importance and relevant substrates. This review will focus on: 1.) CYP1A1 and CYP1B1 from the CYP1 family because of the dual role these enzymes play in the bioactivation of known carcinogens and endogenous compounds. 2.) The targeting of CYPs in hypoxic environments as a therapeutic strategy. 3.) CYP2J2 and its role in the metabolism of arachidonic acid to epoxyeicosatrienoic acids and angiogenesis will also be examined. While much progress has been made towards understanding the role of CYPs in extrahepatic tissue, future studies focused on the development of selective inhibitors coupled with appropriate delivery systems that would target the tumor micro-environments could lead to significant advancement in chemotherapeutic strategies.
Export Options
About this article
Cite this article as:
Raccor S. Brianne and Kaspera Rudiger, Extra-Hepatic Isozymes from the CYP1 and CYP2 Families as Potential Chemotherapeutic Targets, Current Topics in Medicinal Chemistry 2013; 13 (12) . https://dx.doi.org/10.2174/1568026611313120006
DOI https://dx.doi.org/10.2174/1568026611313120006 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biodegradable Biomaterials
Recent Patents on Biomedical Engineering (Discontinued) Why Does Obesity Increase the Risk for Cardiovascular Disease?
Current Pharmaceutical Design New Copper Compounds with Antiplatelet Aggregation Activity
Medicinal Chemistry Sirolimus and its Analogs and its Effects on Vascular Diseases
Current Pharmaceutical Design Cellular Therapy of Lysosomal Storage Disorders: Current Status and Future Prospects
Current Pediatric Reviews Reactive Oxygen Species Formation by Polymorphonuclear Cells and Mononuclear Cells as a Risk Factor of Cardiovascular Diseases
Current Pharmaceutical Biotechnology Rational Basis for Nutraceuticals in the Treatment of Glaucoma
Current Neuropharmacology Crocetin: an Agent Derived from Saffron for Prevention and Therapy for Cancer
Current Pharmaceutical Biotechnology Potential Role of Inflammation in Associations between Particulate Matter and Heart Failure
Current Pharmaceutical Design Novel Inhibitors of HIV Discovered Among Existing Classes of Pharmaceutical Compounds Indicated for Unrelated Clinical Indications
Current Pharmaceutical Design IDO and Clinical Conditions Associated with Depressive Symptoms
Current Drug Metabolism Low-Cost Anti-HIV Compounds: Potential Application for AIDS Therapy in Developing Countries
Current Pharmaceutical Design Cognitive Function and the Ageing Process: The Peculiar Role of Mild Thyroid Failure
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Catechol-O-Methyltransferase (COMT)-Mediated Methylation Metabolism of Endogenous Bioactive Catechols and Modulation by Endobiotics and Xenobiotics: Importance in Pathophysiology and Pathogenesis
Current Drug Metabolism Evaluation of the Anti-Hypercholesterolemic and Antioxidant Activity of Mentha pulegium (L.) Aqueous Extract in Normal and Streptozotocin- Induced Diabetic Rats
The Natural Products Journal The Nutrigenetics and Pharmacogenetics of Vitamin D Pathways
Current Pharmacogenomics and Personalized Medicine Fetal Undernutrition and the Programming of Blood Pressure
Current Nutrition & Food Science Pharmacoproteomics in Cardiac Hypertrophy and Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Link between Metabolic Syndrome and Insulin Resistance
Current Vascular Pharmacology Vascular Effects of Antiarrhythmic Drugs and the Roles of K+ Channels
Current Medicinal Chemistry - Cardiovascular & Hematological Agents